A newly filed class action lawsuit against Pfizer follows a series of legal challenges related to the recall of a drug used for treating sickle-cell disease. This comes as a federal judge recently dismissed another lawsuit against the company, citing protections under the Public Readiness and Emergency Preparedness (PREP) Act and the Federal Food, Drug, and Cosmetic Act (FDCA). In related news, the University of Pennsylvania is set to receive $467 million as part of a settlement that includes $400 million in royalties for the Pfizer-BioNTech vaccine from 2020 through 2023. Additionally, a federal judge upheld a $7.8 million verdict for six transit workers in the Bay Area who were fired for refusing the COVID-19 vaccine, reinforcing the ongoing legal discourse surrounding vaccine mandates and public health measures.